No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Johnson & Johnson is to spin off its orthopaedics unit, the US healthcare giant confirmed on Tuesday, as it posted above-forecast quarterly numbers.
J&J said the planned separation represented the "best path forward" for all stakeholders as well as positioning the division - to be called DePuy Synthes - "for long-term success".
It is expected to take between 18 and 24 months to complete.
The unit, which makes knee, hip and other orthopaedic replacements, reported full-year sales of $9.2bn last year. It is set to become the world's largest specialist orthopaedics firm once the separation is complete.
But J&J chief executive Joaquin Duato acknowledged last month that the division was not a fast-growing segment for the company.
The update came as J&J - which is increasingly focused on more high margin divisions, such as oncology - posted third-quarter sales of $24bn, up 6.8% or by 5.4% on a constant currency basis. The increase was ahead of Wall Street forecasts.
Adjusted diluted earnings per share rose 15.7% to $2.80.
Duato said third-quarter trading had been fuelled by "the depth and strength of our portfolio, and significant progress across our pipeline.
"With a sharpened focus on the six priority areas of oncology, immunology, neuroscience, cardiovascular, surgery and vision, [the company] is in a new era of accelerated growth and innovation."
Looking to the full year, reported sales were expected to come in between $93.5bn and $93.9bn, compared to a previous forecast for between $93.2bn and $93.6bn.
As at 1545 BST, shares in J&J, which have put on 30% so far this year, were off 1%.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.